{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T02:47:51Z","timestamp":1769568471661,"version":"3.49.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Outside of pregnancy, placental growth factor (PlGF), is produced by erythroid cells in typically undetectable levels. In pregnancy, PlGF is strongly expressed by the trophoblast layer covering the placental villi. PlGF levels rise progressively due to placental growth, peak at 28 to 30 weeks gestation, and then slowly decline toward term. Low PlGF has emerged as a powerful diagnostic test for preterm preeclampsia. However, its interpretation in context of sickle cell disease (SCD) is potentially confounded by upregulation of cellular PlGF expression in nonpregnant individuals with SCD, and higher third trimester circulating PlGF levels documented in healthy Black compared with White individuals. Primary objectives were to determine the distribution of PlGF at midtrimester in pregnant individuals with SCD compared with unaffected Black controls and to explore the diagnostic accuracy of PlGF in the context of suspected preeclampsia in pregnancies of individuals with SCD. Secondary objective was to examine the relationship between low PlGF and placental disease in pregnancies of individuals with SCD. Pregnant individuals with SCD at Mount Sinai Hospital in Canada (January 2017 to September 2021) with at least 1 PlGF measurement 20+0 to 35+6 weeks gestation, and pregnant Black controls without SCD with suspected preeclampsia or growth restriction, were included in this retrospective study. Maternal and neonatal outcomes were extracted from medical records. For early-onset, but not late-onset, preeclampsia, a PlGF cutoff of &amp;lt;100 pg\/mL demonstrated 100% sensitivity and specificity at 20 to 24 weeks gestation. This study is, to our knowledge, the first to demonstrate the utility of PlGF in predicting early-onset preeclampsia in pregnancies of individuals with SCD, allowing clinicians to anticipate and mitigate adverse pregnancy outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016821","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:51:46Z","timestamp":1761054706000},"page":"402-412","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Utility of placental growth factor for preeclampsia prediction in pregnancies complicated by sickle cell disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4330-6862","authenticated-orcid":false,"given":"Evangelia","family":"Vlachodimitropoulou","sequence":"first","affiliation":[{"name":"1Division of Maternal-Fetal Medicine, Mount Sinai Hospital, Toronto, ON, Canada"},{"name":"2Faculty of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tharshini","family":"Balasubramaniam","sequence":"additional","affiliation":[{"name":"1Division of Maternal-Fetal Medicine, Mount Sinai Hospital, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-6256","authenticated-orcid":false,"given":"Nadine","family":"Shehata","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"3Department of Medicine and Laboratory Medicine and Pathobiology, Mount Sinai Hospital, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4807-8603","authenticated-orcid":false,"given":"Richard","family":"Ward","sequence":"additional","affiliation":[{"name":"4Division of Haematology, University Health Network, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-9238","authenticated-orcid":false,"given":"Kevin H. M.","family":"Kuo","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"4Division of Haematology, University Health Network, Toronto, ON, Canada"},{"name":"5Scarborough Health Network, Scarborough, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7411-5535","authenticated-orcid":false,"given":"John C.","family":"Kingdom","sequence":"additional","affiliation":[{"name":"1Division of Maternal-Fetal Medicine, Mount Sinai Hospital, Toronto, ON, Canada"},{"name":"6Department of Obstetrics and Gynecology, University of Toronto, Hamilton, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3466-7570","authenticated-orcid":false,"given":"A. Kinga","family":"Malinowski","sequence":"additional","affiliation":[{"name":"1Division of Maternal-Fetal Medicine, Mount Sinai Hospital, Toronto, ON, Canada"},{"name":"6Department of Obstetrics and Gynecology, University of Toronto, Hamilton, ON, Canada"},{"name":"7Division of Maternal-Fetal Medicine, Hamilton Health Sciences Centre, ON, Canada"},{"name":"8Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"23","key":"2026012709315378400_bib1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"2026012709315378400_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.semdp.2011.07.005","article-title":"Pathology of sickle cell disease","volume":"29","author":"Malowany","year":"2012","journal-title":"Semin Diagn Pathol"},{"issue":"07","key":"2026012709315378400_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4236\/abb.2013.47A1002","article-title":"Cytokine profiles in sickle cell anemia: pathways to be unraveled","volume":"04","author":"Pitanga","year":"2013","journal-title":"Adv Biosci Biotechnol"},{"issue":"2","key":"2026012709315378400_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/10739680490278402","article-title":"The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy","volume":"11","author":"Hebbel","year":"2004","journal-title":"Microcirculation"},{"issue":"1","key":"2026012709315378400_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.blre.2016.08.004","article-title":"Placental growth factor: what hematologists need to know","volume":"31","author":"Newell","year":"2017","journal-title":"Blood Rev"},{"key":"2026012709315378400_bib6","doi-asserted-by":"publisher","DOI":"10.1177\/1753495X251327462","article-title":"Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt1): powerful new tools to guide obstetric and medical care in pregnancy","author":"Gladstone","year":"3  2025","journal-title":"Obstet Med"},{"issue":"2S","key":"2026012709315378400_bib7","doi-asserted-by":"crossref","first-page":"S1145","DOI":"10.1016\/j.ajog.2021.08.027","article-title":"Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction","volume":"226","author":"McLaughlin","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2026012709315378400_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/1471-0528.17296","article-title":"Effect of race on the measurement of angiogenic factors for prediction and diagnosis of pre-eclampsia","volume":"130","author":"Wright","year":"2023","journal-title":"BJOG"},{"issue":"10297","key":"2026012709315378400_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(20)32335-7","article-title":"Pre-eclampsia","volume":"398","author":"Chappell","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2026012709315378400_bib10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/HYPERTENSIONAHA.108.117358","article-title":"Early and late preeclampsia","volume":"52","author":"Valensise","year":"2008","journal-title":"Hypertension"},{"issue":"11","key":"2026012709315378400_bib11","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/1471-0528.17837","article-title":"Phenotypes of maternal vascular malperfusion placental pathology and adverse pregnancy outcomes: a retrospective cohort study","volume":"131","author":"Zur","year":"2024","journal-title":"BJOG"},{"issue":"10","key":"2026012709315378400_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/1471-0528.12195","article-title":"Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study","volume":"120","author":"Myers","year":"2013","journal-title":"BJOG"},{"issue":"8","key":"2026012709315378400_bib13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S1701-2163(15)30511-9","article-title":"Altered hemodynamics and hyperuricemia accompany an elevated sFlt-1\/PlGF ratio before the onset of early severe preeclampsia","volume":"36","author":"Doherty","year":"2014","journal-title":"J Obstet Gynaecol Can"},{"issue":"1","key":"2026012709315378400_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/HYPERTENSIONAHA.121.17267","article-title":"Induction of the PPARgamma (Peroxisome Proliferator-Activated Receptor gamma)-GCM1 (Glial Cell Missing 1) Syncytialization Axis Reduces sFLT1 (Soluble fms-Like Tyrosine Kinase 1) in the preeclamptic placenta","volume":"78","author":"Armistead","year":"2021","journal-title":"Hypertension"},{"issue":"5","key":"2026012709315378400_bib15","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/HYPERTENSIONAHA.119.13360","article-title":"Predictive performance of PlGF (placental growth factor) for screening preeclampsia in asymptomatic women: a systematic review and meta-analysis","volume":"74","author":"Agrawal","year":"2019","journal-title":"Hypertension"},{"issue":"21","key":"2026012709315378400_bib16","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2014-11-607317","article-title":"Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis","volume":"125","author":"Oteng-Ntim","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2026012709315378400_bib17","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/bjh.19133","article-title":"Natural history of blood pressure in sickle cell disease pregnancy","volume":"204","author":"Early","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"2026012709315378400_bib18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/bjh.19248","article-title":"Blood pressure thresholds for the diagnosis of hypertensive disorders of pregnancy in sickle cell disease","volume":"204","author":"Early","year":"2024","journal-title":"Br J Haematol"},{"issue":"6","key":"2026012709315378400_bib19","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/HYPERTENSIONAHA.121.17047","article-title":"PlGF (placental growth factor) testing in clinical practice: evidence from a Canadian Tertiary Maternity Referral Center","volume":"77","author":"McLaughlin","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"2026012709315378400_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","article-title":"Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice","volume":"72","author":"Brown","year":"2018","journal-title":"Hypertension"},{"issue":"2","key":"2026012709315378400_bib21","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1542\/peds.108.2.e35","article-title":"A new and improved population-based Canadian reference for birth weight for gestational age","volume":"108","author":"Kramer","year":"2001","journal-title":"Pediatrics"},{"issue":"19","key":"2026012709315378400_bib22","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1161\/CIRCULATIONAHA.113.003215","article-title":"Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study","volume":"128","author":"Chappell","year":"2013","journal-title":"Circulation"},{"key":"2026012709315378400_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.preghy.2020.10.005","article-title":"Placental growth factor measurements in the assessment of women with suspected preeclampsia: a stratified analysis of the PARROT trial","volume":"23","author":"Duhig","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"2026012709315378400_bib40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.5858\/arpa.2015-0225-CC","article-title":"Sampling and definitions of placental lesions: Amsterdam Placental Workshop Group Consensus Statement","volume":"140","author":"Khong","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"2026012709315378400_bib24","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1182\/blood-2002-11-3422","article-title":"Placenta growth factor activates monocytes and correlates with sickle cell disease severity","volume":"102","author":"Perelman","year":"2003","journal-title":"Blood"},{"issue":"21","key":"2026012709315378400_bib25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1392.1392","article-title":"Increased von Willebrand factor and high circulating placental growth factor correlate with inflammation and iron overload in patients with compound heterozygous sickle cell and beta-thalassemia","volume":"124","author":"Voskaridou","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2026012709315378400_bib26","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1182\/blood-2009-04-217950","article-title":"Placenta growth factor in sickle cell disease: association with hemolysis and inflammation","volume":"115","author":"Brittain","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2026012709315378400_bib27","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1600-0412.2011.01186.x","article-title":"A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy","volume":"90","author":"Palm","year":"2011","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"2026012709315378400_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.117.10182","article-title":"Meta-analysis and systematic review to assess the role of soluble FMS-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhirE Study","volume":"71","author":"Agrawal","year":"2018","journal-title":"Hypertension"},{"issue":"3","key":"2026012709315378400_bib29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000178143","article-title":"Increased serum levels of anti-angiogenic factors soluble fms-like tyrosine kinase and soluble endoglin in sickle cell disease","volume":"120","author":"Landburg","year":"2008","journal-title":"Acta Haematol"},{"key":"2026012709315378400_bib30","doi-asserted-by":"crossref","first-page":"l2381","DOI":"10.1136\/bmj.l2381","article-title":"Pre-eclampsia: pathophysiology and clinical implications","volume":"366","author":"Burton","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"2026012709315378400_bib31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2026012709315378400_bib32","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/bjh.17671","article-title":"Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline","volume":"194","author":"Oteng-Ntim","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"2026012709315378400_bib33","doi-asserted-by":"crossref","first-page":"342.e341","DOI":"10.1016\/j.ajog.2023.12.031","article-title":"Aspirin for evidence-based preeclampsia prevention trial: effects of aspirin on maternal serum pregnancy-associated plasma protein A and placental growth factor trajectories in pregnancy","volume":"231","author":"Rolnik","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"2026012709315378400_bib34","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jogc.2021.01.018","article-title":"Second trimester placental growth factor levels and placental histopathology in low-risk nulliparous pregnancies","volume":"43","author":"Audette","year":"2021","journal-title":"J Obstet Gynaecol Can"},{"key":"2026012709315378400_bib35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.preghy.2021.05.023","article-title":"Placental growth factor as a diagnostic tool for placental mediated fetal growth restriction","volume":"25","author":"Shinar","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"2026012709315378400_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.placenta.2020.04.003","article-title":"Placental histopathology in sickle cell disease: a descriptive and hypothesis-generating study","volume":"95","author":"Malinowski","year":"2020","journal-title":"Placenta"},{"issue":"11","key":"2026012709315378400_bib37","doi-asserted-by":"crossref","first-page":"e2444454","DOI":"10.1001\/jamanetworkopen.2024.44454","article-title":"Midpregnancy placental growth factor screening and early preterm birth","volume":"7","author":"Gladstone","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2026012709315378400_bib38","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/17474086.2022.2149488","article-title":"Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids: a comprehensive review","volume":"15","author":"Ferreira de Matos","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"26","key":"2026012709315378400_bib39","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/blood.2021014473","article-title":"Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease","volume":"139","author":"Walter","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/402\/2498041\/blooda_adv-2025-016821-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/402\/2498041\/blooda_adv-2025-016821-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:32:02Z","timestamp":1769524322000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/2\/402\/547850\/Utility-of-placental-growth-factor-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016821","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,27]]},"published":{"date-parts":[[2026,1,15]]}}}